ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month Low - What's Next?

Key Points

• ArriVent BioPharma fell to a new 52-week low of $11.66, last trading near $12.00 versus a prior close of $28.46. Its market capitalization is approximately $584 million.
• Analyst sentiment remains broadly positive, with eight Buy ratings, one Hold and one Sell; the average price target is $44.86, though targets range from $40 to $47.
• The company reported a quarterly loss of $1.05 per share, missing the consensus estimate of $0.99, while analysts expect a full-year loss of approximately $4.11 per share.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) reached a new 52-week low during trading on Tuesday. The company traded as low as $11.66 and last traded at $12.00, with a volume of 1687237 shares traded. The stock had previously closed at $28.46.

Analysts Set New Price Targets

A number of research firms have recently commented on AVBP. Citigroup reduced their price objective on shares of ArriVent BioPharma from $43.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, August 13th. HC Wainwright boosted their price objective on ArriVent BioPharma from $44.00 to $47.00 and gave the stock a "buy" rating in a report on Monday, August 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of ArriVent BioPharma in a report on Friday, July 17th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ArriVent BioPharma in a research report on Tuesday, September 22nd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $45.00 target price on shares of ArriVent BioPharma in a report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $44.86.

ArriVent BioPharma Stock Performance

The company has a 50 day moving average price of $29.86 and a 200 day moving average price of $29.48. The company has a market capitalization of $584.18 million, a price-to-earnings ratio of -3.24 and a beta of 1.34.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.06). Research analysts forecast that ArriVent BioPharma, Inc. will post -4.11 EPS for the current year.

Institutional Investors Weigh In On ArriVent BioPharma

Large investors have recently modified their holdings of the stock. Hhlr Advisors LTD. purchased a new stake in ArriVent BioPharma during the second quarter valued at about $136,498,000. BlackRock Inc. bought a new stake in ArriVent BioPharma during the 2nd quarter valued at $112,919,000. General Catalyst Group Management LLC purchased a new stake in shares of ArriVent BioPharma during the second quarter worth about $51,929,000. Vivo Capital LLC purchased a new position in shares of ArriVent BioPharma during the first quarter valued at approximately $20,438,000. Finally, Seven Fleet Capital Management LP lifted its position in shares of ArriVent BioPharma by 390.7% in the 2nd quarter. Seven Fleet Capital Management LP now owns 246,606 shares of the company's stock worth $8,567,000 after purchasing an additional 196,354 shares during the period. Hedge funds and other institutional investors own 9.48% of the company's stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent's lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.